When mapping tau PET by amyloid PET–inferred tauopathy groups, we found higher baseline tau PET SUVRs and faster change rates with increasing amyloid PET–inferred tauopathy stages (Figure 2D). The gene discussed is MAPT; the disease is amyloidosis.